(Q37948837)

25 August 2017

1 reference

title

The role of endocrine therapy in prostatic cancer (English)

1 reference

25 August 2017

Eaton CL

1

1 reference

25 August 2017

Griffiths K

series ordinal

2

1 reference

25 August 2017

publication date

1 March 1990

1 reference

Bailliere's clinical endocrinology and metabolism

25 August 2017

published in

1 reference

25 August 2017

volume

4

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

85-96

1 reference

Bioavailability, distribution and pharmacokinetics of diethystilbestrol produced from stilphostrol

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Specific Prolactin Binding Sites in the Prostate and Testis of Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Orchiectomy for advanced prostatic carcinoma A reevaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Adrenalectomy and hypophysectomy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Characterization of insulin receptors in isolated epithelial cells of rat ventral prostate: effect of fasting.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Luteinizing Hormone-Releasing Hormone-Induced Regulation of Gonadotropin and Prolactin Receptors in the Rat Testis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

GnRH receptors and actions in the control of reproductive function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

The Isolation and Characterisation of Nerve Growth Factor from the Prostate Gland of the Guinea‐Pig

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Complete primary structure of prostatropin, a prostate epithelial cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Phase II study of megestrol acetate for metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Growth factor receptors and oncogene expression in prostate cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Growth factor involvement and oncogene expression in prostatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Estrogen receptors in human prostate: evidence for multiple binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Pituitary irradiation in advanced carcinoma of the prostate: analysis of 100 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Effect of Megestrol Acetate (Megace®) on Steroid Metabolism and Steroid-Protein Binding in the Human Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Treatment of advanced cancer of prostate with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Aminoglutethimide in advanced prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

QUANTITATIVE STUDIES OF PROSTATIC SECRETION : II. THE EFFECT OF CASTRATION AND OF ESTROGEN INJECTION ON THE NORMAL AND ON THE HYPERPLASTIC PROSTATE GLANDS OF DOGS.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Mitogenic factor in human prostate extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Megestrol acetate for treatment of advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Treatment of Advanced Prostatic Carcinoma with Estracyt: A Preliminary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Selective osteoblast mitogens can be extracted from prostatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Pharmacological and clinical studies of the antiandrogen Anandron

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Estrogen receptors in the human prostate, seminal vesicle, epididymis, testis, and genital skin: a marker for estrogen-responsive tissues?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

A human prostatic growth factor (hPGF): partial purification and characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urolo

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

On the Mechanism of the Anti-androgenic Action ofFlutamide (α-α-α-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide)in the Rat

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Isolation and properties of the FSH and LH-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

LH-RH Agonists and Antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

New methods of endocrine management of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Transphenoidal hypophysectomy in the management of carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Cyproterone Acetate in the Treatment of Advanced Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Advanced prostatic carcinoma Flutamide therapy after conventional endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Experience with Flutamide in Previously Untreated Patients With Advanced Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Ketoconazole therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Proceedings: The natural history of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Prostatic Cancer: Treatment with Long-acting LHRH Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980317-9

7 January 2021

10.1016/S0950-351X(05)80317-9

Identifiers

DOI

1 reference

release_e5paxzmlcvgufpk6pkk5k53qzq

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e5paxzmlcvgufpk6pkk5k53qzq

24 November 2022

mapped directly with Wikidata item

1 reference